We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Verrica Parmaceuticals Inc | NASDAQ:VRCA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.77 | 7.97 | 8.98 | 0 | 01:00:00 |
From May 2023 to May 2024
By Denny Jacob
AMC Entertainment's proposed equity transactions were blocked after a judge rejected a proposed court settlement. Shares surged 74% in after-hours trading.
Medical technology company Becton Dickinson's updated BD Alaris Infusion System received 510(k) clearance from the Food and Drug Administration. Shares climbed 5.9% in aftermarket trading.
Verrica Pharmaceuticals' Ycanth topical solution for the treatment of molluscum contagiosum in adults and patients ages two and up was approved by the Food and Drug Administration. Shares slip 12% in after-hours trading.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
July 21, 2023 19:13 ET (23:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Verrica Parmaceuticals Chart |
1 Month Verrica Parmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
